[go: up one dir, main page]

SI1214061T1 - Use of docetaxel for treating hepatocellular carcinoma - Google Patents

Use of docetaxel for treating hepatocellular carcinoma

Info

Publication number
SI1214061T1
SI1214061T1 SI200030478T SI200030478T SI1214061T1 SI 1214061 T1 SI1214061 T1 SI 1214061T1 SI 200030478 T SI200030478 T SI 200030478T SI 200030478 T SI200030478 T SI 200030478T SI 1214061 T1 SI1214061 T1 SI 1214061T1
Authority
SI
Slovenia
Prior art keywords
docetaxel
hepatocellular carcinoma
treating hepatocellular
treating
mum
Prior art date
Application number
SI200030478T
Other languages
English (en)
Slovenian (sl)
Inventor
Chin-Wen Chi
Heng-Liang Lin
Tsung-Yun Liu
Wing-Yiu Lui
Gar-Yang Chau
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of SI1214061T1 publication Critical patent/SI1214061T1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
SI200030478T 1999-08-31 2000-08-29 Use of docetaxel for treating hepatocellular carcinoma SI1214061T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9920548.6A GB9920548D0 (en) 1999-08-31 1999-08-31 Treatment of hepatocellular carcinoma
PCT/EP2000/008782 WO2001015675A2 (en) 1999-08-31 2000-08-29 Use of docetaxel for treating hepatocellular carcinoma
EP00964144A EP1214061B1 (en) 1999-08-31 2000-08-29 Use of docetaxel for treating hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
SI1214061T1 true SI1214061T1 (en) 2004-12-31

Family

ID=10860081

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030478T SI1214061T1 (en) 1999-08-31 2000-08-29 Use of docetaxel for treating hepatocellular carcinoma

Country Status (34)

Country Link
US (2) US20030158249A1 (cs)
EP (1) EP1214061B1 (cs)
JP (1) JP4866522B2 (cs)
KR (1) KR100670416B1 (cs)
CN (1) CN1174748C (cs)
AT (1) ATE269700T1 (cs)
AU (1) AU777583B2 (cs)
BG (1) BG65913B1 (cs)
BR (1) BR0013625A (cs)
CA (1) CA2382294C (cs)
CZ (1) CZ301378B6 (cs)
DE (1) DE60011794T2 (cs)
DK (1) DK1214061T3 (cs)
EA (1) EA004804B1 (cs)
EE (1) EE05124B1 (cs)
ES (1) ES2218223T3 (cs)
GB (1) GB9920548D0 (cs)
HK (1) HK1048944B (cs)
HR (1) HRP20020171A2 (cs)
HU (1) HU228861B1 (cs)
IL (2) IL147489A0 (cs)
ME (1) MEP7809A (cs)
MX (1) MXPA02002041A (cs)
NO (1) NO328527B1 (cs)
NZ (1) NZ517604A (cs)
PL (1) PL212612B1 (cs)
PT (1) PT1214061E (cs)
RS (1) RS50148B (cs)
SI (1) SI1214061T1 (cs)
SK (1) SK286378B6 (cs)
TW (1) TW589180B (cs)
UA (1) UA72927C2 (cs)
WO (1) WO2001015675A2 (cs)
ZA (1) ZA200201408B (cs)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268619C (zh) 2003-05-08 2006-08-09 上海迪赛诺化学制药有限公司 多烯紫杉醇三水化合物的制备方法
EP1694660B1 (en) * 2003-12-12 2009-04-08 Quiral Quimica Do Brasil Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
PT1931321T (pt) 2005-08-31 2019-05-14 Abraxis Bioscience Llc Composições compreendendo agentes farmacêuticos pouco hidrossolúveis e agentes antimicrobianos
CA2620389C (en) 2005-08-31 2014-06-17 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
EP2146695A4 (en) * 2007-04-23 2010-05-19 Sun Pharmaceuticals Ind Ltd PHARMACEUTICAL COMPOSITIONS
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
CN104784121A (zh) 2010-03-26 2015-07-22 阿布拉科斯生物科学有限公司 治疗肝细胞癌的方法
MX341082B (es) * 2010-05-03 2016-08-08 Teikoku Pharma Usa Inc Formulaciones de pro-emulsion de taxano no acuosas y metodos para hacer y usar las mismas.
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP3258913A1 (en) * 2015-02-17 2017-12-27 Mallinckrodt Nuclear Medicine LLC Modified docetaxel liposome formulations and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629819B1 (fr) * 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
CA2150372C (en) * 1993-01-19 2002-08-20 Nancy L. Mills Stable oral ci-981 formulation and process of preparing same
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
CA2628857C (en) * 1996-12-30 2011-09-13 Batelle Memorial Institute Formulation and method for treating neoplasms by inhalation
EP1023050B1 (en) * 1997-06-27 2013-09-25 Abraxis BioScience, LLC Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
AU1146099A (en) * 1997-09-18 1999-04-05 Janssen Pharmaceutica N.V. Fused imidazole derivatives for improving oral bioavailability of pharmaceuticalagents
EP1027045A4 (en) * 1997-10-31 2004-12-08 Arch Dev Corp METHODS AND COMPILATIONS FOR REGULATING S-ALPHA REDUCTASE ACTIVITY
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
EP1140194A2 (en) * 1998-12-23 2001-10-10 G.D. SEARLE & CO. Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
CN101370774A (zh) * 2005-12-13 2009-02-18 特瓦制药工业有限公司 阿托伐他汀半钙的晶形及其制备方法

Also Published As

Publication number Publication date
KR20020060166A (ko) 2002-07-16
DE60011794T2 (de) 2005-07-14
HUP0203197A3 (en) 2005-01-28
IL147489A (en) 2006-06-11
KR100670416B1 (ko) 2007-01-17
EA200200313A1 (ru) 2002-08-29
RS50148B (sr) 2009-05-06
EP1214061A2 (en) 2002-06-19
JP4866522B2 (ja) 2012-02-01
PL353198A1 (en) 2003-11-03
CZ2002739A3 (cs) 2002-06-12
EA004804B1 (ru) 2004-08-26
ME00624B (me) 2011-12-20
CA2382294C (en) 2008-06-03
PT1214061E (pt) 2004-09-30
UA72927C2 (uk) 2005-05-16
CA2382294A1 (en) 2001-03-08
WO2001015675A3 (en) 2001-09-20
NO328527B1 (no) 2010-03-08
DE60011794D1 (de) 2004-07-29
DK1214061T3 (da) 2004-11-01
EE05124B1 (et) 2009-02-16
EP1214061B1 (en) 2004-06-23
HUP0203197A2 (hu) 2003-01-28
CN1372466A (zh) 2002-10-02
US20080045584A1 (en) 2008-02-21
YU11402A (sh) 2005-07-19
ATE269700T1 (de) 2004-07-15
AU7516800A (en) 2001-03-26
HK1048944A1 (en) 2003-04-25
MEP7809A (en) 2011-12-20
AU777583B2 (en) 2004-10-21
GB9920548D0 (en) 1999-11-03
HRP20020171A2 (en) 2004-02-29
ES2218223T3 (es) 2004-11-16
NO20020829L (no) 2002-02-20
MXPA02002041A (es) 2002-08-20
CZ301378B6 (cs) 2010-02-03
HU228861B1 (hu) 2013-06-28
HK1048944B (zh) 2005-04-22
IL147489A0 (en) 2002-08-14
BG65913B1 (bg) 2010-05-31
WO2001015675A2 (en) 2001-03-08
CN1174748C (zh) 2004-11-10
BG106460A (bg) 2002-09-30
EE200200087A (et) 2003-04-15
SK286378B6 (sk) 2008-08-05
NZ517604A (en) 2004-04-30
ZA200201408B (en) 2003-07-30
SK2712002A3 (en) 2002-07-02
BR0013625A (pt) 2002-05-14
PL212612B1 (pl) 2012-10-31
TW589180B (en) 2004-06-01
JP2003508427A (ja) 2003-03-04
NO20020829D0 (no) 2002-02-20
US20030158249A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
IL147489A0 (en) Use of docetaxel for treating hepatocellular carcinoma
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
GB0223038D0 (en) Therapeutic compounds
GB0225474D0 (en) Therapeutic agents
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
NZ511201A (en) Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
DE60204966D1 (de) Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
SI1968573T1 (sl) Uporaba benzo-kondenziranih heterocikliäśnih sulfamidnih derivatov za zdravljenje manije in bipolarne motnje
GB0020504D0 (en) Therapeutic method
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
SI1603584T1 (sl) Aplidin za zdravljenje multiple mieloma
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
MXPA02008870A (es) Novedosos antagonistas de lhrh, produccion de los mismos y sus uso como medicamentos.
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
GR1004434B (el) Χρησηατουαdiclofenacαhααποδεκτωνααλατωνααυτουαγιαατηνααντιμετωπισηατωναεγκαυματων
WO2005094282A3 (en) Combination therapy comprising cloretazinetm
UA32314A (uk) Спосіб лікування некротичного панкреатиту
UA34199A (uk) Спосіб лікування пародонтиту
TW200505836A (en) Cyclic sulfonamides for inhibition of gamma-secretase
DE60208336D1 (de) Kombination von aktiva mit alfuzosin und apomorphin
UA95094C2 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства